A Comprehensive Model for Enrofloxacin to Ciprofloxacin Transformation and Disposition in Dog
- 1 October 1997
- journal article
- Published by American Geophysical Union (AGU) in Journal of Pharmaceutical Sciences
- Vol. 86 (10), 1148-1155
- https://doi.org/10.1021/js9603461
Abstract
The pharmacokinetics of enrofloxacin and ciprofloxacin, its major active metabolite, were determined in dog after oral and intravenous administrations of enrofloxacin and intravenous infusion of ciprofloxacin. A comprehensive model of enrofloxacin and ciprofloxacin disposition was constructed to investigate the extent of enrofloxacin to ciprofloxacin transformation and the influence of the hepatic first-pass effect on the parent compound oral bioavailability. Plasma levels were measured using a validated HPLC method. Enrofloxacin and ciprofloxacin plasma concentration data were fitted simultaneously using a set of differential equations describing a six-compartment model (two compartments for each analyte, one for the liver, and one for the intestinal tract); it was assumed that only a fraction of enrofloxacin was metabolized to ciprofloxacin and that this conversion only occurred in the liver. The fitted parameters obtained from the model were used to calculate plasma clearances (0.729 +/- 0.212 L/h/kg for enrofloxacin, 0.468 +/- 0.094 L/h/kg for ciprofloxacin), distribution volumes (2.45 +/- 0.49 L/kg for enrofloxacin, 1.92 +/- 0.33 L/kg for ciprofloxacin), mean residence times (3.47 +/- 0.78 h for enrofloxacin, 4.20 +/- 0.82 h for ciprofloxacin), and the fractions of enrofloxacin metabolized to ciprofloxacin after intravenous and oral administrations of enrofloxacin. It was shown that enrofloxacin was largely metabolized to ciprofloxacin and that the fractions of metabolized enrofloxacin were similar after intravenous and oral administrations of enrofloxacin (40.44 +/- 10.08 and 40.17 +/- 8.33%, respectively), the hepatic first-pass effect being low (7.15 +/- 1.99%).Keywords
This publication has 11 references indexed in Scilit:
- Pharmacokinetics of marbofloxacin in dogs after oral and parenteral administrationJournal of Veterinary Pharmacology and Therapeutics, 1996
- Pharmacokinetics of enrofloxacin after single intravenous, intramuscular and subcutaneous injections in lactating cowsJournal of Veterinary Pharmacology and Therapeutics, 1995
- Enrofloxacin‐theophylline interaction: influence of enrofloxacin on theophylline steady‐state pharmacokinetics in the Beagle dogJournal of Veterinary Pharmacology and Therapeutics, 1995
- Pharmacokinetics of enrofloxacin and its metabolite ciprofloxacin after intravenous and oral administration of enrofloxacin in dogsJournal of Veterinary Pharmacology and Therapeutics, 1993
- Analytical Methods Validation: Bioavailability, Bioequivalence, and Pharmacokinetic StudiesJournal of Pharmaceutical Sciences, 1992
- General treatment of mean residence time, clearance, and volume parameters in linear mammillary models with elimination from any compartmentJournal of Pharmacokinetics and Biopharmaceutics, 1988
- The role of estrogen receptor in Xenopus laevis vitellogenin gene expressionAmerican Journal of Physiology-Cell Physiology, 1982
- A program for non-linear regression analysis to be used on desk-top computersComputer Programs in Biomedicine, 1980
- Interspecies variation in liver weight, hepatic blood flow, and antipyrine intrinsic clearance: Extrapolation of data to benzodiazepines and phenytoinJournal of Pharmacokinetics and Biopharmaceutics, 1980
- Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equationsJournal of Pharmacokinetics and Biopharmaceutics, 1978